PFIZER INC (1PFE.MI) Stock Price, Forecast & Analysis
BIT:1PFE • US7170811035
1PFE.MI Key Statistics, Chart & Performance
The current stock price of 1PFE.MI is 23.53 EUR. In the past month the price increased by 6.88%. In the past year, price decreased by -9.15%.
1PFE.MI Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to 1PFE.MI. When comparing the yearly performance of all stocks, 1PFE.MI is a bad performer in the overall market: 65.14% of all stocks are doing better.
1PFE.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to 1PFE.MI. While 1PFE.MI is still in line with the averages on profitability rating, there are concerns on its financial health.
1PFE.MI Financial Highlights
Over the last trailing twelve months 1PFE.MI reported a non-GAAP Earnings per Share(EPS) of 2.72. The EPS increased by 3.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.65% | ||
| ROA | 4.71% | ||
| ROE | 10.59% | ||
| Debt/Equity | 0.62 |
1PFE.MI Forecast & Estimates
33 analysts have analysed 1PFE.MI and the average price target is 24.87 EUR. This implies a price increase of 5.68% is expected in the next year compared to the current price of 23.53.
For the next year, analysts expect an EPS growth of -7.02% and a revenue growth -1.57% for 1PFE.MI
1PFE.MI Ownership
1PFE.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SNW | SANOFI | 9.22 | 188.271B | ||
| 1SAN | SANOFI | 9.21 | 188.078B | ||
| SAN | SANOFI | 9.18 | 187.474B | ||
| MRK | MERCK KGAA | 14.87 | 55.565B | ||
| UCB | UCB SA | 27.18 | 54.365B | ||
| UNC | UCB SA | 26.19 | 52.381B | ||
| BAYN | BAYER AG-REG | 9.41 | 45.177B | ||
| 1BAYN | BAYER AG-REG | 9.41 | 45.142B | ||
| IPN | IPSEN | 13.56 | 12.965B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 10.593B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1PFE.MI
Company Profile
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 81,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
Company Info
PFIZER INC
66 Hudson Boulevard East
New York City NEW YORK US
Employees: 81000
Phone: 13026587581
PFIZER INC / 1PFE.MI FAQ
What does PFIZER INC do?
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 81,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
What is the stock price of PFIZER INC today?
The current stock price of 1PFE.MI is 23.53 EUR. The price increased by 1.03% in the last trading session.
Does 1PFE stock pay dividends?
PFIZER INC (1PFE.MI) has a dividend yield of 6.26%. The yearly dividend amount is currently 1.42.
How is the ChartMill rating for PFIZER INC?
1PFE.MI has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the GICS sector and industry of 1PFE stock?
PFIZER INC (1PFE.MI) operates in the Health Care sector and the Pharmaceuticals industry.
How is the valuation of PFIZER INC (1PFE.MI) based on its PE ratio?
The PE ratio for PFIZER INC (1PFE.MI) is 8.65. This is based on the reported non-GAAP earnings per share of 2.72 and the current share price of 23.53 EUR.
What is the expected growth for 1PFE stock?
The Revenue of PFIZER INC (1PFE.MI) is expected to decline by -1.57% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.